Department of Oncology, General Hospital, Jinan Command of the People's Liberation Army, Jinan, China.
Breast Cancer Res Treat. 2013 Sep;141(2):213-24. doi: 10.1007/s10549-013-2679-7. Epub 2013 Sep 14.
Cytoplasmic HuR is associated with reduced survival in invasive breast cancer. We designed this study to determine the predictive and prognostic value of HuR expression in women with breast cancer who underwent neoadjuvant chemotherapy followed by surgical resection. We immunohistochemically analyzed cytoplasmic HuR expression in tumor biopsy cores obtained from 139 patients with invasive breast cancers who received paclitaxel and anthracycline-based neoadjuvant chemotherapy. We evaluated the relationship of HuR expression level with pathologic complete response (pCR), local recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), recurrence-free survival (RFS), and overall survival (OS). Cytoplasmic HuR expression was present in 60 cases (43.2 %). The expression of cytoplasmic HuR was significantly associated with high nuclear grade (P < 0.0001) and ER (P = 0.001) and PR (P = 0.005) status. Multivariate regression analysis further revealed that high nuclear grade (P = 0.023), negative ER status (P = 0.043), and human epidermal growth factor receptor 2 (HER2) overexpression (P < 0.0001), but not cytoplasmic HuR expression, were significant independent predictors of pCR. Interestingly, multivariate Cox analysis revealed that cytoplasmic HuR expression was a strong independent predictor of reduced LRFS (P = 0.014), DRFS (P = 0.001), RFS (P < 0.0001), and OS (P = 0.019) irrespective of pCR. Furthermore, the patient group with tumors showing both expression of cytoplasmic HuR and non-pCR had a worse prognosis in LRFS (P = 0.048), DRFS (P < 0.0001), RFS (P < 0.0001), and OS (P = 0.001) than did other patient groups; patients with tumors showing negative cytoplasmic expression of HuR and pCR had the best prognosis in all RFS and OS. Cytoplasmic expression of HuR is an independent prognostic marker in breast cancer patients undergoing chemotherapy. Combination analyses of HuR expression and pCR, compared with pCR alone, can better predict clinical outcome in patients with primary breast cancer.
细胞质 HuR 与浸润性乳腺癌患者生存降低相关。我们设计了这项研究以确定在接受紫杉醇和蒽环类药物新辅助化疗后行手术切除的乳腺癌患者中 HuR 表达的预测和预后价值。我们对 139 例接受紫杉醇和蒽环类药物新辅助化疗的浸润性乳腺癌患者的肿瘤活检核心进行了细胞质 HuR 免疫组化分析。我们评估了 HuR 表达水平与病理完全缓解（pCR）、局部无复发生存（LRFS）、远处无复发生存（DRFS）、无复发生存（RFS）和总生存（OS）之间的关系。细胞质 HuR 表达存在于 60 例（43.2%）患者中。细胞质 HuR 的表达与高核分级（P < 0.0001）和 ER（P = 0.001）和 PR（P = 0.005）状态显著相关。多变量回归分析进一步表明，高核分级（P = 0.023）、ER 阴性（P = 0.043）和人表皮生长因子受体 2（HER2）过表达（P < 0.0001），但不是细胞质 HuR 表达，是 pCR 的显著独立预测因子。有趣的是，多变量 Cox 分析显示，细胞质 HuR 表达是 LRFS（P = 0.014）、DRFS（P = 0.001）、RFS（P < 0.0001）和 OS（P = 0.019）降低的独立强预测因子，与 pCR 无关。此外，细胞质 HuR 表达和非 pCR 同时存在的肿瘤患者在 LRFS（P = 0.048）、DRFS（P < 0.0001）、RFS（P < 0.0001）和 OS（P = 0.001）方面的预后较差，而细胞质 HuR 表达阴性和 pCR 的患者在所有 RFS 和 OS 方面的预后最佳。细胞质 HuR 表达是接受化疗的乳腺癌患者的独立预后标志物。与单独 pCR 相比，HuR 表达与 pCR 的联合分析可以更好地预测原发性乳腺癌患者的临床结局。
